Stay updated with breaking news from Compugen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, announced today...
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies.
LONDON (dpa-AFX) - Compugen Ltd. (CGEN) said it expects to receive a milestone payment of $7.5 million from AstraZeneca, after AstraZeneca dosed the first patient in ARTEMIDE phase 2 study with
/PRNewswire/ -- DelveInsight's 'TIGIT Inhibitors Competitive Landscape – 2022' report provides comprehensive global coverage of available, marketed, and...
TIGIT Inhibitors clinical trial pipeline constitutes 18+ key companies continuously working towards developing 20+ TIGIT inhibitors drugs, analyzes DelveInsight LAS VEGAS, Nov. 16, 2022